Amylyx Pharmaceuticals, Inc. AMLX
Set alert
At close · Oct 30
After hours · Oct 30, 4:33 PM ET
- YTD
- +138.91%
- 1 year
- +105.41%
- Open
- 28.41
- Prev close
- 28.68
- Mkt cap
- 3.62B
- Vol
- 989.52K
- Avg vol
- 2.21M
- EPS
- -1.41
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 28.00
- High
- 29.09
- Forward P/E
- -26.47
- Beta
- -0.09
- Short ratio
- 9.49
- Inst. own
- 94.37%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 31.11
- 200-d avg
- 20.00
- 1y target
- 43.00
5D chart
Signals (140)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 29, 3:45 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:25 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 1:15 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 12:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:15 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:05 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:00 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 12:00 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 11:55 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:50 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 11:40 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 11:35 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:35 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:10 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:45 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 1:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:25 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 12:00 PM | 3 days ago |
| SMA: Bearish | Oct 28, 11:50 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:40 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 10:40 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:25 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:15 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:15 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:10 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:00 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 9:35 AM | 3 days ago |
| RSI: Overbought | Oct 27, 3:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:45 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:30 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:15 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 12:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 12:00 PM | 4 days ago |
| SMA: Bullish | Oct 27, 11:45 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:20 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:15 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:20 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:10 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 4 days ago |
| RSI: Overbought | Oct 27, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:45 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:35 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:00 PM | 5 days ago |
| SMA: Bearish | Oct 26, 11:25 AM | 5 days ago |
| SMA: Bearish | Oct 26, 11:20 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:15 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 11:10 AM | 5 days ago |
| MACD: Sell Signal | Oct 26, 10:35 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 10:20 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:15 AM | 5 days ago |
| SMA: Bearish | Oct 26, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 26, 9:50 AM | 5 days ago |
| SMA: Bearish | Oct 26, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 26, 9:40 AM | 5 days ago |
| RSI: Oversold | Oct 26, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 23, 3:45 PM | 1 week ago |
| SMA: Bullish | Oct 23, 3:40 PM | 1 week ago |
| RSI: Oversold | Oct 23, 3:15 PM | 1 week ago |
| MACD: Sell Signal | Oct 23, 3:05 PM | 1 week ago |
| SMA: Bearish | Oct 23, 2:55 PM | 1 week ago |
| MACD: Buy Signal | Oct 23, 2:50 PM | 1 week ago |
| SMA: Bullish | Oct 23, 2:40 PM | 1 week ago |
| SMA: Bearish | Oct 23, 2:35 PM | 1 week ago |
| MACD: Sell Signal | Oct 23, 1:55 PM | 1 week ago |
| SMA: Bullish | Oct 23, 1:45 PM | 1 week ago |
| SMA: Bearish | Oct 23, 1:40 PM | 1 week ago |
| SMA: Bearish | Oct 23, 1:35 PM | 1 week ago |
| SMA: Bullish | Oct 23, 1:30 PM | 1 week ago |
| SMA: Bullish | Oct 23, 1:30 PM | 1 week ago |
| SMA: Bearish | Oct 23, 1:25 PM | 1 week ago |
| SMA: Bullish | Oct 23, 1:20 PM | 1 week ago |
| SMA: Bearish | Oct 23, 1:15 PM | 1 week ago |
| SMA: Bearish | Oct 23, 1:15 PM | 1 week ago |
| SMA: Bullish | Oct 23, 1:00 PM | 1 week ago |
| SMA: Bullish | Oct 23, 1:00 PM | 1 week ago |
| SMA: Bearish | Oct 23, 12:55 PM | 1 week ago |
| SMA: Bearish | Oct 23, 12:55 PM | 1 week ago |
| SMA: Bullish | Oct 23, 12:30 PM | 1 week ago |
| SMA: Bullish | Oct 23, 12:30 PM | 1 week ago |
| SMA: Bearish | Oct 23, 12:20 PM | 1 week ago |
| SMA: Bullish | Oct 23, 11:55 AM | 1 week ago |
| SMA: Bearish | Oct 23, 11:40 AM | 1 week ago |
| SMA: Bullish | Oct 23, 11:35 AM | 1 week ago |
| SMA: Bearish | Oct 23, 11:10 AM | 1 week ago |
| SMA: Bullish | Oct 23, 11:05 AM | 1 week ago |
| SMA: Bearish | Oct 23, 11:00 AM | 1 week ago |
| SMA: Bullish | Oct 23, 10:55 AM | 1 week ago |
News
-
2 weeks ago benzinga.com
Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $39
Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $32 to $39.
2 weeks ago schaeffersresearch.com
11 Stocks Most Likely to See a Short Squeeze Rally
Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.
-
3 weeks ago benzinga.com
Amylyx Pharma To Present Phase 3 Topline Data Highlighting Avexitide’s Efficacy And Safety At ObesityWeek 2026 Annual Meeting
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced it will present two presentations at the upcoming ObesityWeek® 2026 Annual Meeting, taking place November 14-17,
3 weeks ago businesswire.com
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting.
3 weeks ago benzinga.com
Amylyx Pharma Q2 2026 Earnings Call Transcript
Amylyx Pharma (NASDAQ:AMLX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For…
3 weeks ago defenseworld.net
Dyadic International (NASDAQ:DYAI) & Amylyx Pharmaceuticals (NASDAQ:AMLX) Critical Review
Amylyx Pharmaceuticals (NASDAQ: AMLX - Get Free Report) and Dyadic International (NASDAQ: DYAI - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the…
4 weeks ago marketbeat.com
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment
Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to…
1 month ago schaeffersresearch.com
10 Stocks With Massive Short Squeeze Potential
Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into Q4. Where are short sellers putting their money?
1 month ago seekingalpha.com
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago fool.com
Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH
Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility.
1 month ago fool.com
Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?
FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.
2 months ago fool.com
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
Amylyx Pharmaceuticals raised $500 million to strengthen its balance sheet. A potential 2027 drug launch could provide the company's next catalyst.
2 months ago defenseworld.net
BlackRock Inc. Acquires New Stake in Amylyx Pharmaceuticals, Inc. $AMLX
BlackRock Inc. bought a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange…
2 months ago defenseworld.net
BlackRock Inc. Acquires New Stake in Amylyx Pharmaceuticals, Inc. $AMLX
BlackRock Inc. bought a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange…
2 months ago marketwatch.com
20 stocks likely to lose money even if the bull market continues
Certain stocks are such poor bets that they are likely to lose ground even in bull markets.
-
2 months ago benzinga.com
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57
Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $55 to $57.
2 months ago defenseworld.net
Almitas Capital LLC Buys Shares of 974,881 Amylyx Pharmaceuticals, Inc. $AMLX
Almitas Capital LLC acquired a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent Form 13F filing with the Securities and…
2 months ago defenseworld.net
Deutsche Bank AG Takes Position in Amylyx Pharmaceuticals, Inc. $AMLX
Deutsche Bank AG bought a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent filing with the SEC. The fund bought 557,937 shares of the…
2 months ago benzinga.com
Benzinga Bulls and Bears: Ross, Moderna, Webull
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
2 months ago fool.com
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week
Analysts also raised their price targets on the company. On top of that, it launched a new round of capital raising.
2 months ago gurufocus.com
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (âAmylyxâ or the âCompanyâ) today announced the pricing of an upsized underwritten public offering of 14,090
2 months ago businesswire.com
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an upsized underwritten public offering of…
-
2 months ago benzinga.com
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $42
Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $30 to $42.
2 months ago zacks.com
AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win
Amylyx surges after avexitide cuts hypoglycemic events 55% in phase III LUCIDITY study, paving the way for an FDA filing by end-2026 in PBH.
-
2 months ago benzinga.com
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55
Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $40 to $55.
-
2 months ago benzinga.com
Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52
Baird analyst Joel Beatty maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $28 to $52.
2 months ago benzinga.com
Profusa, Baidu, Amylyx Pharmaceuticals, FreeCast and Klarna Group: Why These 5 Stocks Are on Investors' Radars Today
PFSA, BIDU, AMLX, CAST, KLAR were among the stocks seen trending on Tuesday, Aug. 18, 2026.
2 months ago fool.com
Why Amylyx Pharmaceuticals Stock Skyrocketed Today
Amylyx is developing a GLP-1 treatment for people with chronic low blood sugar. The experimental therapy displayed a favorable safety profile in a clinical study.
2 months ago businesswire.com
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of $350.0…
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55
HC Wainwright & Co. analyst Andrew S. Fein maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $34 to $55.
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers AIxCrypto Hldgs (NASDAQ:AIXC) stock increased by 132.0% to $1.65 during Tuesday's regular session. The market value of their outstanding shares is at $14.3 million. Amylyx Pharmaceuticals…
2 months ago benzinga.com
Crude Oil Gains 1%; US Pending Home Sales Fall In July
US stocks fell in midday trading, with S&P 500 down 0.5% and Dow dropping 0.17%. Health care shares rose 1.6%, while tech stocks fell 2.1%.
2 months ago benzinga.com
Duos Technologies Posts Upbeat Q2 Results, Joins Amylyx Pharmaceuticals, Weave Communications And Other Big Stocks Moving Higher On Tuesday
US stocks down, Nasdaq falls 300+ points. Duos Tech shares rise on better Q2 results. Many other big stocks gain, including Duolingo, Intuit, and Newsmax.
2 months ago benzinga.com
Amylyx Pharmaceuticals Comes Closer to Potentially Delivering First Treatment for Weight Loss Surgery-Related Low Suger Level
Amylyx Pharmaceuticals posts positive Phase 3 avexitide data for post-bariatric hypoglycemia. The company plans a 2026 FDA application.
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Amylyx Pharmaceuticals (NASDAQ:AMLX) stock increased by 27.5% to $27.32 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.3 billion. bioAffinity…
-
2 months ago benzinga.com
Market-Moving News for August 18th
XOS: 140% | Xos shares are trading higher after the company announced that it has been awarded a prototype Other Transaction Agreement by the United States Air Force to develop and deliver a…
-
2 months ago benzinga.com
Amylyx Pharmaceuticals Says LUCIDITY Phase 3 Trial Met Its Primary Endpoint, Demonstrating 55% Reduction in Level 2 and Level 3 Hypoglycemic Events Vs. Placebo
LUCIDITY met FDA-agreed-upon primary endpoint; avexitide demonstrated a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo (p=0.000003)LUCIDITY met all…
2 months ago benzinga.com
Why Flexsteel Industries Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Flexsteel Industries Inc (FLXS) reported better-than-expected Q4 results, with shares jumping 9% in pre-market trading. Other gainers include PFSA, EJH, XOS, WETO, SGLY, VOGX, WFF, AMLX, and ENRD.…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after-market session. The company's market cap stands at $1.7 million. The company's, Q2 earnings came out…
2 months ago benzinga.com
Amylyx Pharmaceuticals Stock Soars After the Close: Here's Why
Amylyx Pharmaceuticals shares are trading higher Monday after the company scheduled a Phase 3 trial results readout for this week.
-
2 months ago benzinga.com
Amylyx Pharmaceuticals To Announce Phase 3 LUCIDITY Trial Topline Results For Avexitide In Post-Bariatric Hypoglycemia On August 18 At 8:00 a.m. ET
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18,
-
2 months ago benzinga.com
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $30
Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $24 to $30.
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
7 months ago benzinga.com
Beyond Meat Posts Downbeat Q4 Results, Joins RH, ORIC Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
US stock futures higher with Dow up 200 pts, Beyond Meat shares drop after downbeat results; ORIC, RH, Aptiv, Sweetgreen, Nike, and others also decline.
8 months ago benzinga.com
This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
Top Wall Street analysts changed outlook on top names. Check out analyst ratings page for all changes. AMLX, OFRM, AGMB, SGP initiated with positive outlook.
12 months ago benzinga.com
Earnings Scheduled For November 6, 2025
Earnings Scheduled For November 6, 2025
1 year ago benzinga.com
Carnival Posts Better-Than-Expected Earnings, Joins Liminatus Pharma, Coinbase Global, Uber And Other Big Stocks Moving Higher On Tuesday
Carnival Posts Better-Than-Expected Earnings, Joins Liminatus Pharma, Coinbase Global, Uber And Other Big Stocks Moving Higher On Tuesday
1 year ago benzinga.com
This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday
This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday